Education
About Us
Working with TipRanks
Follow Us
Inogen (INGN)
NASDAQ:INGN
INGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.14 - $13.33
Previous CloseN/A
Volume110.44K
Average Volume (3M)343.29K
Market Cap
$198.41M
Enterprise Value$126.28M
Total Cash (Recent Filing)$196.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next Earnings
May 01, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding23,818,413
10 Day Avg. Volume469,895
30 Day Avg. Volume343,292
Standard Deviation0.17
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.60
Price to Cash Flow (P/CF)7.10
P/FCF Ratio9.30
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.00
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$10.00Price Target Upside20.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Inogen News
PremiumCompany Announcements
Inogen Inc’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Inogen Reports Strong Revenue Growth in 2024
PremiumCompany Announcements
Inogen Board Reshuffle with Sahney Appointment---
Bulls Say, Bears Say
Bulls Say
Revenue GrowthInogen's B2B sales beat estimates due to new customer wins, increased business from existing customers, and further share gains from Philips.
Strategic PartnershipsINGN announced a new strategic collaboration with the Chinese medical device manufacturer Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Bears Say
Direct-to-Consumer ChallengesDTC sales missed estimates due to a decline in sales rep headcount.
---
Ownership Overview
1.53% Insiders
21.27% Mutual Funds
30.23% Other Institutional Investors
35.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INGN FAQ
What was Inogen’s price range in the past 12 months?
Inogen lowest stock price was $6.14 and its highest was $13.33 in the past 12 months.
What is Inogen’s market cap?
Inogen’s market cap is $198.41M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is May 01, 2025 which is in 58 days.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on Feb 25, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.608 by $0.198.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.44.
How many shares outstanding does Inogen have?
Inogen has 23,818,413 shares outstanding.
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.608. Following the earnings report the stock price went down -14.811%.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in INGN
---
Inogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (20.05% Upside)
$10.00 (20.05% Upside)
Blogger Sentiment
Bullish
INGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 274.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 15.2%
Last 30 Days ▼ 15.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.43%
12-Months-Change
Fundamentals
Return on Equity
-18.95%
Trailing 12-Months
Asset Growth
-9.20%
Trailing 12-Months
Company Description
Inogen
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
---
INGN Company Deck
---
INGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Inogen's earnings call highlighted notable achievements in revenue growth, strategic collaborations, and product innovations, contributing positively to the company's outlook. However, challenges remain with declines in direct-to-consumer and rental revenues, alongside a continued net loss. The positive aspects, especially strategic partnerships and product clearances, suggest optimism for future growth.Read More>---
INGN Stock 12 Month Forecast
Average Price Target
$10.00
▲(20.05% Upside)
Technical Analysis
Boston Scientific
―
Orthofix
―
Zimmer Biomet Holdings
―
Nevro Corp
―
TransMedics Group
―
Best Analysts Covering INGN
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+24.64%
reiterated a sell rating 4 months ago
Copying Robbie Marcus's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.64% per trade.
---